UNSPSC 51393107: Guanoxabenz hydrochloride

This classification denotes an alpha-adrenergic agonist with the molecular formula C8H8Cl2N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ASL1V61E48, chemically known as hydrazinecarboximidamide, 2-((2,6-dichlorophenyl)methylene)-n-hydroxy-, hydrochloride (1:1), but more generally known as guanoxabenz hydrochloride, which bears US NIH Compound Identifier 17750940.

European Medicines Agency schedules guanoxabenz hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14038MIG. Most nations, for tariff purposes, schedule guanoxabenz hydrochloride under HS 29280090. SMILES: C1CC(C(C(C1)CL)/C=N/NC(=N)NO)CL.CL.

UNSPSC 51393107 Guanoxabenz hydrochloride is a Commodity code that captures pharmaceutical and medical products procured by state and local health agencies, though recent opportunities under this code do not align with the specific chemical compound named. The single recent solicitation record shows a Seminole County, Florida procurement classified under this code but actually soliciting naloxone and safe drug deactivation systems — opioid-overdose reversal agents and related harm-reduction equipment rather than guanoxabenz, an antihypertensive compound. State and local procurement offices tag medical and pharmaceutical products inconsistently across UNSPSC codes, and this code shows minimal relevant recent activity for the compound it nominally describes.

Seminole County Community Health, a Florida county health department, posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The original response deadline was July 26, 2023, and the contract included a two-year initial term with a one-year renewal option. Bidders were required to submit unit costs for each line item, comply with drug-free workplace and E-Verify requirements, maintain workers' compensation and commercial general liability insurance, and cover all shipping and delivery costs. The procurement was potentially funded through FEMA, introducing additional federal compliance requirements under the Clean Air Act and Federal Water Pollution Control Act. No explicit set-aside designations were noted. The geographic activity and issuing-body mix for this code remain unclear given the single opportunity on record and its mismatch to the code's nominal pharmaceutical scope.